Amor Hajri completed his Diploma of clinical biology in the Faculty of Medicine, Tunis. Thereafter, he continued his education in Strasbourg at the University of Louis Pasteur (France), where he obtained in 1986 his M.S. degree of biochemistry and molecular/cellular biology. In 1987, he received his Postgraduate degree “Molecular and cellular pharmacology” and in 1992, he received his Ph.D. degree “Pharmacology/oncology” from the Faculty of Pharmacy. After postdoc experience, “Sandoz/Basel-INSERM U61/Strasbourg” (1993-1994), he joined the Digestive Cancer Research Institute, where he developed his own research lab (1994–2008). In 2009, Dr. Hajri joined FRIAS Institute at the University of Freiburg as a Senior Scientist. He has a membership of European Pancreatic Club, American Society of Gene Therapy, Secretary of the French Club of Pancreas, and he is a reviewer of the editorial review boards of many cancer and gene therapy journals. Hajri’s research activities were carried out through different research programs: Carcinogenesis, Cancer Cell Biology, and Molecular Cancer Therapeutics with particular interest in pancreatic adenocarcinoma. During the first years, his research program was primarily focused on photodynamic therapy strategy for colon cancer and pancreatic adenocarcinoma treatment. Thereafter, his main interest was focused on the development of new multimodal treatment based on gene therapy and oncolytic virotherapy strategies. His current research project is more focused on the role of different transcription factors in tumor growth and metastasis. He is investigating the role of the transcriptional factor AP1 in cancer development and developing new therapeutic strategy using AP1 interfering peptides. New phage display technologies are used for peptides interfering selection targeting the coiled coil domain of oncogenic transcription factors (such as c-Jun, c-Fos, and c-Myc).
Biography Updated on 5 January 2011